Sarepta Therapeutics, Inc. (NASDAQ: SRPT) today announced that it has initiated dosing in a confirmatory study of eteplirsen, the Company’s ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE